What question did this study set out to answer?

This research aims to explore the impact of COVID-19 on mucormycosis cases and assess therapeutic options.

March 8, 2026Open Access

COVID-19 associated mucormycosis and their therapeutics

Key Points

This research aims to explore the impact of COVID-19 on mucormycosis cases and assess therapeutic options.
Review of treatment options for COVID-19 related mucormycosis including antifungal therapies.
Discussion of co-morbidities linked to heightened risk.
Analysis of the role of iron and zinc in mucormycosis.
Exploration of various clinical types of mucormycosis.
First-line treatments include liposomal amphotericin B and its analogs.
Second-line therapies feature posaconazole and isavuconazole.
Surgical debridement is critical in effective management.
Early detection significantly improves patient outcomes.

Abstract

Mucormycosis has spread rapidly in the COVID-19 and post-COVID-19 patients having low immunity and co-morbidities. It is also related to excessive use of corticosteroids, immunosuppressants, antibiotics, and unhygienic conditions. The efforts have been made to treat COVID-19 and post-COVID-19 associated mucormycosis. The first line of therapy includes liposomal amphotericin B, amphotericin B lipid complex and amphotericin B deoxycholate, while posaconazole and isavuconazole were effective as a second line of therapy. Notably, surgical debridement is an essential step in the treatment and is usually used along with antifungal therapy in the first line of treatment.We have discussed COVID-19 and post-COVID-19 associated mucormycosis patients along with their co-morbidities and treatments. The discussion also included the role of iron and zinc in COVID-19 associated mucormycosis (CAM), mechanism of COVID-19 associated mucormycosis (CAM), its clinical trials, therapeutics of COVID-19 associated mucormycosis (CAM) involving liposomal amphotericin B (LAmB), Amphotericin B and mechanism of their action, mechanism of action of Azoles, different types of Covid-19 associated mucormycosis (CAM) patients including those having pulmonary mucormycosis, rhino-cerebral mucormycosis, cutaneous mucormycosis, rhino-orbital mucormycosis, gastrointestinal mucormycosis and sino-orbital mucormycosis and their therapeutics and surgical management of mucormycosis.Furthermore, a clean, hygienic, and healthy environment should be maintained to avoid COVID-19 and post-COVID-19 associated mucormycosis. The early detection of COVID-19 associated mucormycosis (CAM) and post-COVID-19 associated mucormycosis determines the patients’ outcome. The early diagnosis of post-COVID-19 associated mucormycosis can be achieved by following up COVID-19 patients who had previously received corticosteroids as COVID-19 treatment. Thus, early detection and treatment of COVID-19 associated mucormycosis (CAM) and post-COVID-19-associated mucormycosis may help control the high mortality rate and facilitate better management.

COVID-19 associated mucormycosis and their therapeutics

Key Points

Abstract

Cite This Study